Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financi...(Equity Series A convertible preferred...)

Date:8/14/2009

Equity Series A, convertible preferred stock, $0.001 par value, 5,000,000 shares authorized, None issued and outstanding -- -- Undesignated preferred stock, $.001 par value, 5,000,000 shares authorized, None issued and outstanding -- -- Common stock, $.001 par value, 100,000,000 shares authorized, 23,240,899 shares issued and outstanding at June 30, 2009 and December 31, 2008 23,241 23,241 Additional paid-in capital 10,430,168 10,430,168 Statutory reserves 5,731,880 1,585,383 Retained earnings 12,534,367 10,996,655 Accumulated other comprehensive income 248,834 237,658 Total Stockholders' Equity 28,968,490 23,273,105 Total Liabilities and Stockholders' Equity $36,257,390 $28,997,639 BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended Six Months Ended June 30, June 30, 2009 2008 2009 2008 Sales, net $13,245,042 $9,420,774 $20,692,706 $16,231,033 Cost of sales 3,509,754 4,028,527 6,168,561 6,667,206 Gross profit 9,735,288 5,392,247 14,524,145 9,563,827 Selling, general and administrative expenses 4,271,308 3,374,617 6,751,292 5,427,295 Income from operations 5,463,980 2,017,630 7,772,853 4,136,532 Other Income (Expense) Interest income 183 1,442 493 1,521 Interest expense -- (1
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
2. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
3. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
4. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
5. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
9. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
10. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement